NCT03906357No Longer Available不适用
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A Study of Regorafenib in Advanced Pancreatic Cancer PatientsPancreatic CancerNCT02080260Wake Forest University Health Sciences20
Available
不适用
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseSTAT1 Gain-of-Function DiseaseNCT05561985Incyte Corporation
已完成
2 期
Scheduling Nab-paclitaxel With GemcitabinePancreatic Adenocarcinoma MetastaticNCT03529175CCTU- Cancer Theme146
撤回
2 期
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.Pancreas AdenocarcinomaNCT04045730Yale University
撤回
1 期
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic CancerNCT06017323Georgetown University